Compare Ascendis Pharma A/S (ASND) vs Capital One Financial Corp. (COF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Capital One Financial Corp. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Capital One Financial Corp. trades at $202.02 (market cap $124.14B). The key difference: Capital One Financial Corp. is far larger — about 7× Ascendis Pharma A/S's market cap, and Capital One Financial Corp. pays a 1.59% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | COF | |
|---|---|---|
Market Cap | $17.74B | $124.14B |
Sector | Health | Financials |
52-Week High | $277.18 | $257.94 |
52-Week Low | $163.32 | $176.10 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Capital One (COF) trades at $201.52, up 0.71% with a bearish technical signal but strong analyst support. The company reported mixed Q1 2026 earnings with a slight miss, while revenue surged to $53.43B in 2025. Key risks include subprime auto loan delinquencies and consumer credit stress, though the Discover integration offers long-term scale benefits. Technical indicators show neutral RSI readings with support at $195 and resistance at $203.
Wall Street maintains a bullish outlook with 62.5% buy ratings and a $256.25 consensus price target, representing 27% upside potential. However, declining profit margins and rising default risks in consumer lending create headwinds. The stock presents a compelling entry point for investors betting on operational improvements from recent acquisitions, though credit quality trends warrant close monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →
